Display options
Cite
Troelsgaard A, Pitcher A, Binder R, et al. Health Economic Evaluation of Canagliflozin In The Treatment of Type 2 Diabetes Mellitus In Slovakia. Value Health. 2014;17(7):A345doi: 10.1016/j.jval.2014.08.698.
Troelsgaard, A., Pitcher, A., Binder, R., Stetka, R., Ondrusova, M., Lovato, E., & Hemels, M. (2014). Health Economic Evaluation of Canagliflozin In The Treatment of Type 2 Diabetes Mellitus In Slovakia. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 17(7), A345. https://doi.org/10.1016/j.jval.2014.08.698
Troelsgaard, A, et al. "Health Economic Evaluation of Canagliflozin In The Treatment of Type 2 Diabetes Mellitus In Slovakia." Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research vol. 17,7 (2014): A345. doi: https://doi.org/10.1016/j.jval.2014.08.698
Troelsgaard A, Pitcher A, Binder R, Stetka R, Ondrusova M, Lovato E, Hemels M. Health Economic Evaluation of Canagliflozin In The Treatment of Type 2 Diabetes Mellitus In Slovakia. Value Health. 2014 Nov;17(7):A345. doi: 10.1016/j.jval.2014.08.698. Epub 2014 Oct 26. PMID: 27200647.
Copy Download .nbib Format: NLM
Share it on

Value Health. 2014 Nov;17(7):A345. doi: 10.1016/j.jval.2014.08.698. Epub 2014 Oct 26.

Health Economic Evaluation of Canagliflozin In The Treatment of Type 2 Diabetes Mellitus In Slovakia.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

A Troelsgaard, A Pitcher, R Binder, R Stetka, M Ondrusova, E Lovato, M Hemels

Affiliations

  1. Janssen A/S, Birkerød, Denmark.
  2. IMS Health, London, UK.
  3. Janssen, Bratislava, Slovak Republic.
  4. Pharm-In, Ltd, Bratislava, Slovak Republic.
  5. Pharm-In Ltd, Bratislava, Slovak Republic.

PMID: 27200647 DOI: 10.1016/j.jval.2014.08.698

[No abstract available.]

Publication Types